alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.
Company profile
Ticker
ALIM
Exchange
Website
CEO
Richard Eiswirth
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Alimera Sciences Limited • Alimera Sciences Opthamologie GmbH • Alimera Sciences Europe Limited ...
ALIM stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
8 Mar 24
10-K
2023 FY
Annual report
8 Mar 24
8-K
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
7 Mar 24
S-8
Registration of securities for employees
9 Feb 24
S-8
Registration of securities for employees
9 Feb 24
8-K
Departure of Directors or Certain Officers
9 Feb 24
8-K
Departure of Directors or Certain Officers
4 Jan 24
8-K
Departure of Directors or Certain Officers
12 Dec 23
8-K
Alimera Appoints Maggie A. Pax to Its Board of Directors
8 Nov 23
10-Q
2023 Q3
Quarterly report
1 Nov 23
Transcripts
ALIM
Earnings call transcript
2023 Q4
7 Mar 24
ALIM
Earnings call transcript
2023 Q3
26 Oct 23
ALIM
Earnings call transcript
2023 Q2
10 Aug 23
ALIM
Earnings call transcript
2023 Q1
18 May 23
ALIM
Earnings call transcript
2022 Q4
31 Mar 23
ALIM
Earnings call transcript
2022 Q3
14 Nov 22
ALIM
Earnings call transcript
2022 Q2
30 Jul 22
ALIM
Earnings call transcript
2022 Q1
9 May 22
ALIM
Earnings call transcript
2021 Q4
24 Feb 22
ALIM
Earnings call transcript
2021 Q3
28 Oct 21
Latest ownership filings
4
Philip Ashman
2 Apr 24
4
Jason M. Werner
13 Mar 24
4
Todd Michael Wood
13 Mar 24
4
RICHARD S EISWIRTH JR
13 Mar 24
4
Philip Ashman
13 Mar 24
4
Elliot Maltz
13 Mar 24
SC 13G/A
LYTTON LAURENCE W
14 Feb 24
SC 13G/A
BOOTHBAY FUND MANAGEMENT, LLC
13 Feb 24
SC 13G/A
Stonepine Capital Management, LLC
13 Feb 24
SC 13G/A
HBM Healthcare Investments (Cayman) Ltd.
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.32 mm | 8.32 mm | 8.32 mm | 8.32 mm | 8.32 mm | 8.32 mm |
Cash burn (monthly) | 3.50 mm | (no burn) | (no burn) | 1.41 mm | 3.28 mm | 1.52 mm |
Cash used (since last report) | 23.34 mm | n/a | n/a | 9.40 mm | 21.86 mm | 10.17 mm |
Cash remaining | -15.02 mm | n/a | n/a | -1.08 mm | -13.54 mm | -1.85 mm |
Runway (months of cash) | -4.3 | n/a | n/a | -0.8 | -4.1 | -1.2 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 31 |
Opened positions | 12 |
Closed positions | 0 |
Increased positions | 5 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 146.23 bn |
Total shares | 58.71 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Caligan Partners | 16.84 mm | $52.19 bn |
Velan Capital Investment Management | 13.61 mm | $42.19 bn |
Therapeutics OcuMension | 11.45 mm | $112.21 mm |
Stonepine Capital Management | 3.98 mm | $12.35 bn |
Boothbay Fund Management | 3.20 mm | $9.92 bn |
Altium Capital Management | 2.93 mm | $9.10 bn |
AIGH Capital Management | 2.37 mm | $7.35 bn |
Clearline Capital | 2.34 mm | $7.24 bn |
MS Morgan Stanley | 666.25 k | $2.07 bn |
Worth Venture Partners | 593.71 k | $1.84 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Mar 24 | Philip Ashman | Common Stock | Payment of exercise | Dispose F | No | Yes | 3.83 | 12,103 | 46.35 k | 118,274 |
11 Mar 24 | Jason M. Werner | RSU Common Stock | Grant | Acquire A | No | No | 0 | 1,800 | 0.00 | 1,800 |
11 Mar 24 | Wood Todd Michael | RSU Common Stock | Grant | Acquire A | No | No | 0 | 125,000 | 0.00 | 125,000 |
11 Mar 24 | Wood Todd Michael | RSU Common Stock | Grant | Acquire A | No | No | 0 | 125,000 | 0.00 | 125,000 |
11 Mar 24 | Eiswirth Richard S JR | RSU Common Stock | Grant | Acquire A | No | No | 0 | 14,700 | 0.00 | 14,700 |
11 Mar 24 | Philip Ashman | RSU Common Stock | Grant | Acquire A | No | No | 0 | 75,000 | 0.00 | 75,000 |
11 Mar 24 | Philip Ashman | RSU Common Stock | Grant | Acquire A | No | No | 0 | 6,800 | 0.00 | 6,800 |
News
Maxim Group Initiates Coverage On Alimera Sciences with Buy Rating, Announces Price Target of $10
25 Mar 24
HC Wainwright & Co. Maintains Buy on Alimera Sciences, Raises Price Target to $6
8 Mar 24
Alimera Sciences Q4 EPS $(0.07) Up From $(0.54) YoY, Sales $26.31M Beat $24.34M Estimate
7 Mar 24
Earnings Scheduled For March 7, 2024
7 Mar 24
A Preview Of Alimera Sciences's Earnings
6 Mar 24